Our previous study showed that an
iron chelator and
anticancer agent Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (
Dp44mT) has an antiinflammatory effect in human mast cells. However, antiinflammatory effect of
Dp44mT remains unclear in animal models. In this study, we assessed whether administration of
Dp44mT could relieve clinical symptoms of
ovalbumin (OVA)-induced
allergic rhinitis (AR) mice. After administration of
Dp44mT, number of rubs was significantly decreased, and levels of
histamine and
IgE were suppressed in serum of AR mice. Also, serum levels of
interleukin (IL)-1β,
thymic stromal lymphopoietin (TSLP), and
tumor necrosis factor (TNF)-α increased by OVA challenge were significantly lowered by administration of
Dp44mT. T helper type 1 (Th1)
cytokine interferon-γ level was significantly increased by administration of
Dp44mT, whereas Th2
cytokines such as
IL-4,
IL-5, and
IL-13 were significantly reduced by administration of
Dp44mT. In intranasal tissues of AR mice, levels of IL-1β, TSLP, TNF-α, and
IL-6 and activities and
protein levels of caspase-1 were significantly reduced by administration of
Dp44mT. Interestingly, administration of
Dp44mT reduced number of infiltrated eosinophils and mast cells through the inhibition of macrophage inflammatory protein-2 and
intercellular adhesion molecule-1 in intranasal tissues of AR mice. In conclusion, these results indicate that
Dp44mT also has potential antiinflammatory effects in vivo as well as in vitro.